04:50 PM EST - Ventripoint Diagnostics Ltd : Today announced that its VMS+ technology has been selected for use in AIRES (Artificial Intelligence Reconstruction of Echocardiography Study), a newly launched clinical research study at The Royal Wolverhampton NHS Trust in the United Kingdom. AIRES is described as a world-first study evaluating AI-enabled echocardiography specifically in oncology patients. The research will focus on patients undergoing chemotherapy for breast cancer, a population at risk of developing treatment-related heart complications. Ventripoint Diagnostics Ltd
shares V.VPT are trading off $0.01 at $0.11.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=VPT%3ACC&qmodStoryID=6554407566180453
